Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340646 · ClinicalTrials.gov registry record · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
A NA study of Multiple Myeloma and Colon Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 990
- Enrollment target
- 1
- Study location
NCT06340646: Recruiting NA study of Multiple Myeloma and Colon Cancer, sponsored by Washington University School of Medicine.
NCT06340646 is a NA study of Multiple Myeloma and Colon Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 990 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06340646, a NA study of Multiple Myeloma and Colon Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 990 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.
Primary Outcome
11-item, Likert scale. This scale has 5 points ranging from strongly agree to strongly disagree. 1=Strongly Agree, 2=Agree, 3=Neither Agree nor Disagree, 4=Disagree, 5=Strongly Disagree for items (4, 6-11) are scored such that 'strong disagree' reflects a correct response and 'somewhat disagree' reflects a less confident correct response in the correct direction. Negatively worded items (items 1, 2, 3, and 5) are reverse scored so that 'strongly agree' reflects a correct response and 'somewhat a
Conditions Studied
Interventions
- OTHER Return of Genetic Results: Biomarker information from cancer cells
- OTHER Return of Genetic Results: Inherited mutations related to cancer
- OTHER Return of Genetic Results: Inherited mutations related to other medical issues
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2027-01-31 |
| Phase | NA |
What NCT06340646 shows while recruiting
NCT06340646 is an interventional study that assigns participants to a tested intervention. The registered 990 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% higher).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Return of Genetic Results: Biomarker information from cancer cells is the first listed.
NCT06340646 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06340646 about?
NCT06340646 is a clinical study titled "Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)". The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding r...
What is the current status of trial NCT06340646?
This trial is currently recruiting. It is a NA study. The enrollment target is 990 participants. The study started on 2022-10-18. Estimated completion is 2027-01-31.
What conditions does trial NCT06340646 study?
This clinical trial studies the following conditions: Multiple Myeloma, Colon Cancer, Rectal Cancer, Cholangiocarcinoma.
What interventions are being tested in trial NCT06340646?
The interventions under investigation include: Return of Genetic Results: Biomarker information from cancer cells (OTHER), Return of Genetic Results: Inherited mutations related to cancer (OTHER), Return of Genetic Results: Inherited mutations related to other medical issues (OTHER).
Who is sponsoring clinical trial NCT06340646?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340646 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06340646's enrollment target sits among peer trials
990 23rd of 438 higher than 416 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- NCT06883305 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- NCT07018700 · 990 participants · Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI